Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
- PMID: 12114422
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
Abstract
Purpose: To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma.
Experimental design: Four hundred patients with the following disorders were studied: MGUS (76 patients); smoldering (indolent; early-stage) multiple myeloma (SMM; 112 patients); newly diagnosed, active multiple myeloma (MM; 99 patients); relapsed (advanced) multiple myeloma (RMM; 26 patients); and primary amyloidosis (AL; 87 patients). Forty-two normal control BM samples were studied for comparison. BM angiogenesis was studied in a blinded manner by immunohistochemical staining for CD34 to identify microvessels.
Results: The median (range) microvessel density (MVD) per x400 high power field was 1.3 (0-11) in the controls, 1.7 (0-10) in AL, 3 (0-23) in MGUS, 4 (1-30) in SMM, 11 (1-48) in newly diagnosed MM, and 20 (6-47) in RMM; P < 0.001. MVD was significantly higher in MGUS, SMM, newly diagnosed MM, and RMM compared with controls and AL; P < 0.001. MVD was not significantly different between controls and AL. By grading, high-grade angiogenesis was present in 0% of controls and AL, 1% of MGUS, 3% of SMM, 29% of newly diagnosed MM, and 42% of RMM; P < 0.001. MVD correlated with the BM plasma cell labeling index (rho = 0.46, P < 0.001) and BM plasma cell percentage (rho 0.5, P < 0.001). Survival was 28 months in SMM and newly diagnosed MM with high-grade angiogenesis, compared with 53 months for those with low- and intermediate-grade angiogenesis; P = 0.02.
Conclusions: BM angiogenesis progressively increases along the spectrum of plasma cell disorders, from the more benign MGUS stage to advanced myeloma, indicating that angiogenesis may be related to disease progression.
Similar articles
-
Prognostic value of bone marrow angiogenesis in multiple myeloma.Clin Cancer Res. 2000 Aug;6(8):3111-6. Clin Cancer Res. 2000. PMID: 10955791
-
Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.Am J Hematol. 2006 Sep;81(9):649-56. doi: 10.1002/ajh.20639. Am J Hematol. 2006. PMID: 16845660
-
Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.Clin Cancer Res. 2009 May 1;15(9):3118-25. doi: 10.1158/1078-0432.CCR-08-2310. Epub 2009 Apr 14. Clin Cancer Res. 2009. PMID: 19366830
-
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Blood Rev. 2007 Sep;21(5):255-65. doi: 10.1016/j.blre.2007.01.002. Epub 2007 Mar 26. Blood Rev. 2007. PMID: 17367905 Review.
-
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.Ann Hematol. 2011 Jan;90(1):101-6. doi: 10.1007/s00277-010-1028-8. Epub 2010 Jul 20. Ann Hematol. 2011. PMID: 20645101 Review.
Cited by
-
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.Int J Mol Sci. 2021 Apr 24;22(9):4462. doi: 10.3390/ijms22094462. Int J Mol Sci. 2021. PMID: 33923357 Free PMC article. Review.
-
Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug-induced thromboembolism.Blood Adv. 2024 Feb 13;8(3):785-796. doi: 10.1182/bloodadvances.2023010080. Blood Adv. 2024. PMID: 38163319 Free PMC article.
-
Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.Eur Radiol. 2016 May;26(5):1404-11. doi: 10.1007/s00330-015-3928-4. Epub 2015 Jul 29. Eur Radiol. 2016. PMID: 26215436
-
Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.J Cancer Res Clin Oncol. 2015 Aug;141(8):1503-9. doi: 10.1007/s00432-015-1952-z. Epub 2015 Mar 13. J Cancer Res Clin Oncol. 2015. PMID: 25773125
-
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Blood. 2010 Dec 2;116(23):4906-15. doi: 10.1182/blood-2010-04-276626. Epub 2010 Aug 30. Blood. 2010. PMID: 20805366 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical